Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$107.95

-5.4 (-4.76%)

06:56
10/12/18
10/12
06:56
10/12/18
06:56

Eli Lilly launches Thriver Movement for MBC patients in response to survey

Results from a new national, multi-stakeholder survey commissioned by Eli Lilly revealed that metastatic breast cancer, or MBC, places a significant daily strain on those living with the incurable disease. People with MBC who participated in the survey reported spending nearly half their time each week, 47%, on things related to their cancer. In response to the survey findings, Lilly created the Thriver Movement as part of its More For MBC initiative, which aims to increase understanding of the daily impact of MBC, deliver more dedicated resources and advance the development of more treatment options. Lilly partnered with MBC activist and actress Mira Sorvino as well as celebrity fitness instructor and yoga expert Anna Kaiser to launch the Thriver Movement. To mark the initiative's debut, Lilly collaborated with Kaiser and yoga instructors at the Dana-Farber Cancer Institute to develop a unique Thriver yoga pose and flow which is symbolic of the emotional and physical strength these women and men exude and can be done daily. The Thriver pose represents the strength and never-ending spirit of women living with MBC.

  • 19

    Oct

  • 19

    Oct

  • 06

    Nov

  • 07

    Nov

LLY Eli Lilly
$107.95

-5.4 (-4.76%)

10/05/18
10/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei citing the prospects of its LY3298176, a GIP and GLP-1 dual receptor agonist presented at EASD 54th Annual Meeting, which he believes "meaningfully improves" the company's long-term growth prospects. 2. Helmerich & Payne (HP) upgraded to Overweight from Equalweight at Capital One. 3. Canadian Pacific (CP) upgraded to Buy from Hold at TD Securities. 4. Eni SpA (E) and Equinor (EQNR) were upgraded to Buy from Neutral at BofA/Merrill. 5. Fiesta Restaurant (FRGI) upgraded to Neutral from Underweight at Piper Jaffray with analyst Nicole Miller Regan saying the company has recently reported better than expected results and sustained a return to positive same-store sales trends. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/18
10/05/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. HP CUT TO NEUTRAL AT JPMORGAN: JPMorgan analyst Paul Coster downgraded HP Inc. (HPQ) to Neutral from Overweight while raising his price target for the shares to $29 from $28. Despite the company's "excellent execution," the shares have limited catalysts ahead, Coster told investors in a research note following the company's analyst day. The analyst recommended investors take profits with the stock up 24% year-to-date. HP shares were lower by 1.9% to $25.91 in late morning trading. ELI LILLY UPGRADED TO OUTPERFORM AT BMO: BMO Capital analyst Alex Arfaei upgraded Eli Lilly (LLY) to Outperform from Market Perform and raised his price target on the shares to $130 from $107. The analyst cited the prospects of LY3298176, a GIP and GLP-1 dual receptor agonist presented at EASD 54th Annual Meeting, which he believes "meaningfully improves" the company's long-term growth prospects. Arfaei sees "continued strong growth of the GLP-1 class" and anticipates an annualized revenue growth of about 15% through 2027, adding that he is also positive on Eli Lilly's margins and its other indications in fields such as obesity. Eli Lilly shares were higher by 1.8% to $115.01 in late morning trading. PEPSI CUT TO NEUTRAL AT MACQUARIE: Macquarie analyst Caroline Levy downgraded Pepsi (PEP) to Neutral from Outperform and cut its price target to $107 from $122 following the company's Q3 report. Levy noted that Pepsi reported solid Q3 organic sales growth of 5%, but EBIT margins fell do to increased brand spending, higher input costs abroad due to FX hikes, and higher freight. The analyst said she expects these pressures to remain a drag on margins and cut estimates to reflect dilution from the Sodastream acquisition, tougher comps, and lack of tax reform benefits. Further, Levy expects organic sales growth will require more investment while costs continue to climb. ROKU STARTED WITH A NEUTRAL AT WEDBUSH: Wedbush analyst Michael Pachter initiated Roku (ROKU) with a Neutral rating and $73 price target. While Roku has built an "exceptional" platform on the back of its players and is positioning itself as the best-in-class option for OTT advertising, Roku's growth is fully priced into its share price, Pachter told investors in a research note. The analyst believes that any pullback may provide an opportunity to build a position. SUPER MICRO COMPUTER CUT TO HOLD AT MAXIM: Maxim analyst Nehal Chokshi downgraded Super Micro Computer (SMCI) to Hold from Buy. The analyst stated that while the Bloomberg Businessweek article alleging the company's "servers sold to customers contained malicious microchips" were strongly refuted, the detail, the reputable nature of the source, and the number of cross reference checks lend to its credibility. Chokshi further noted that the company's ongoing delay in releasing its 2017 10K filing adds to his concerns, stating that he no longer sees reward relative to risk as asymmetric. Super Micro Computer shares were higher by 3.1% to $12.99 in late morning trading.
10/08/18
10/08/18
DOWNGRADE

Neutral
Novo Nordisk downgraded to Neutral on Eli Lilly competition at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Sachin Jain downgraded Novo Nordisk (NVO) to Neutral from Buy after he lowered his Ozempic forecasts beyond FY23 to account for possible competitive pressure from Eli Lilly's (LLY) GIP/GLP-1. While he does not see competitive pressure on Novo's Ozempic until FY23, he still sees that threat as a sufficient overhang given that the injectable GLP-1 franchise accounts for about 40% of his Novo growth forecast from FY19-23E and about 30% for FY23, Sachin tells investors. He lowered his price target on Novo shares to DKK305 from DKK380.
10/08/18
GUGG
10/08/18
INITIATION
Target $132
GUGG
Buy
Eli Lilly initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez started Eli Lilly with a Buy rating and $132 price target, calling out the company's "Impressive execution as the industry's leading fast-follower." He sees limited downside from current levels with the potential for revaluation around the Phase 3 study readout for tanezumab.

TODAY'S FREE FLY STORIES

TPC

Tutor Perini

$17.72

0.25 (1.43%)

06:25
02/21/19
02/21
06:25
02/21/19
06:25
Hot Stocks
Tutor Perini awarded $253M contract by MTA New York City Transit »

Tutor Perini announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

STNG

Scorpio Tankers

$19.66

-0.28 (-1.40%)

06:24
02/21/19
02/21
06:24
02/21/19
06:24
Conference/Events
Scorpio Tankers management to meet with BTIG »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DIN

Dine Brands

$88.52

1.08 (1.24%)

06:24
02/21/19
02/21
06:24
02/21/19
06:24
Hot Stocks
Dine Brands board approves 10% increase to quarterly dividend to 69c per share »

The company's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GMDA

Gamida Cell

$13.46

0.01 (0.07%)

06:23
02/21/19
02/21
06:23
02/21/19
06:23
Hot Stocks
Gamida Cell presents new data from NAM-NK and NiCord programs »

Gamida Cell announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DIN

Dine Brands

$88.52

1.08 (1.24%)

06:22
02/21/19
02/21
06:22
02/21/19
06:22
Earnings
Dine Brands sees FY19 adjusted EPS $6.90-$7.20, consensus $6.93 »

Applebee's domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LPCN

Lipocine

$1.71

(0.00%)

06:22
02/21/19
02/21
06:22
02/21/19
06:22
Conference/Events
Lipocine management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

KURA

Kura Oncology

$15.06

-0.22 (-1.44%)

06:22
02/21/19
02/21
06:22
02/21/19
06:22
Conference/Events
Kura Oncology management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DIN

Dine Brands

$88.52

1.08 (1.24%)

06:21
02/21/19
02/21
06:21
02/21/19
06:21
Earnings
Dine Brands reports Q4 adjusted EPS $1.70, consensus $1.57 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

JSAIY

J Sainsbury

$0.00

(0.00%)

06:21
02/21/19
02/21
06:21
02/21/19
06:21
Downgrade
J Sainsbury rating change  »

J Sainsbury downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight-Swift

$34.71

0.475 (1.39%)

06:21
02/21/19
02/21
06:21
02/21/19
06:21
Conference/Events
Knight-Swift management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

KIDS

OrthoPediatrics

$38.34

0.96 (2.57%)

06:21
02/21/19
02/21
06:21
02/21/19
06:21
Conference/Events
OrthoPediatrics management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Mar

  • 27

    Mar

GDOT

Green Dot

$74.69

-0.05 (-0.07%)

06:20
02/21/19
02/21
06:20
02/21/19
06:20
Recommendations
Green Dot analyst commentary  »

Green Dot Q4 margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOPE

Grand Canyon

$97.13

0.18 (0.19%)

06:20
02/21/19
02/21
06:20
02/21/19
06:20
Recommendations
Grand Canyon analyst commentary  »

Grand Canyon correction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAI

Kadant

$89.52

1.55 (1.76%)

06:19
02/21/19
02/21
06:19
02/21/19
06:19
Conference/Events
Kadant management to meet with Barrington »

Meeting to be held in St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SCBFF

Standard Chartered

$0.00

(0.00%)

06:19
02/21/19
02/21
06:19
02/21/19
06:19
Periodicals
Standard Chartered earmarks $900M for U.S., UK fines, FT reports »

Standard Chartered has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PQG

PQ Group

$16.71

0.16 (0.97%)

06:18
02/21/19
02/21
06:18
02/21/19
06:18
Earnings
Breaking Earnings news story on PQ Group »

PQ Group sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

PQG

PQ Group

$16.71

0.16 (0.97%)

06:18
02/21/19
02/21
06:18
02/21/19
06:18
Earnings
PQ Group sees FY19 revenue $1.64B-$1.67B, consensus $1.68B »

Sees FY19: Adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

PQG

PQ Group

$16.71

0.16 (0.97%)

06:16
02/21/19
02/21
06:16
02/21/19
06:16
Earnings
PQ Group reports Q4 adjusted EPS 17c, consensus 13c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TEF

Telefonica

$8.73

0.07 (0.81%)

, TIGO

Millicom

$60.25

(0.00%)

06:16
02/21/19
02/21
06:16
02/21/19
06:16
Hot Stocks
Millicom buys Telefonica mobile businesses in Central America for $1.65B »

Millicom International…

TEF

Telefonica

$8.73

0.07 (0.81%)

TIGO

Millicom

$60.25

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 12

    Mar

  • 19

    Mar

  • 19

    Mar

HTGC

Hercules Capital

$13.12

0.07 (0.54%)

06:15
02/21/19
02/21
06:15
02/21/19
06:15
Hot Stocks
Hercules Capital names Seth Meyer as CFO »

Hercules Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

JOUT

Johnson Outdoors

$65.68

-0.23 (-0.35%)

06:15
02/21/19
02/21
06:15
02/21/19
06:15
Conference/Events
Johnson Outdoors management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 28

    Feb

  • 28

    Feb

CGC

Canopy Growth

$46.18

-0.2 (-0.43%)

06:14
02/21/19
02/21
06:14
02/21/19
06:14
Recommendations
Canopy Growth analyst commentary  »

Piper Jaffray remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAP

SAP

$106.91

0.08 (0.07%)

06:14
02/21/19
02/21
06:14
02/21/19
06:14
Hot Stocks
SAP board recommends FY18 dividend increase of 7% to EUR1.50 per share »

The supervisory board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

THRM

Gentherm

$42.86

-0.22 (-0.51%)

06:13
02/21/19
02/21
06:13
02/21/19
06:13
Earnings
Gentherm backs product revenue growth of high single-digit CAGR for 2018-2021 »

Based on 2018 results and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

THRM

Gentherm

$42.86

-0.22 (-0.51%)

06:11
02/21/19
02/21
06:11
02/21/19
06:11
Earnings
Gentherm sees FY19 product revenue $1.01B-$1.04B, consensus $1.1B »

Sees FY19: Operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.